Trial · NCT03231033
Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis
NCT03231033, Phase 1, Completed, Children's Hospital Medical Center, Cincinnati
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis. Trials, record NCT03231033. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03231033
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis
- NCT number
- NCT03231033
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 3 participants, actual
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Conditions
- Autoimmune Pulmonary Alveolar Proteinosis
- Interventions
- Pioglitazone
- First posted
- 2017-07-27
- Last updated
- 2020-01-18
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Occurrence of any treatment-emergent adverse events and serious adverse events | 1 year | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
| Secondary | Alveolar-arterial oxygen concentration gradient (A-aDO2) | 1 year | Change from Baseline (Day 0) in the A-aDO2 gradient as measured at the End of Treatment |
| Secondary | PaO2 | 1 year | Change from Baseline (Day 0) in the PaO2 as measured at the End of Treatment |
| Secondary | Minimum SpO2 during a standardized treadmill exercise test | 1 year | Change from Baseline (Day 0) in the minimum SpO2 during a treadmill exercise test as measured at the End of Treatment |
| Secondary | Time during a standardized treadmill exercise test required for SpO2 to fall below 88% (or discontinuance of testing due to dyspnea) | 1 year | Change from Baseline (Day 0) in the time for the SpO2 to fall below 88% during the treadmill exercise test as measured at the End of Treatment |
| Secondary | DLCO (Diffusion capacity of the lung for carbon monoxide) | 1 year | Change from Baseline (Day 0) in the DLCO as measured at the End of Treatment |
| Secondary | Parenchymal lung density determined by quantitative computed tomography (CT) densitometry | 1 year | Change from Baseline (Day 0) in the parenchymal densitometry as measured at the End of Treatment |
| Secondary | Quality of Life measured by SF-36 | 1 year | Change from Baseline (Day 0) in the quality of life as measured at the End of Treatment |
| Secondary | Quality of Life measured by St. George's Respiratory Questionnaire | 1 year | Change from Baseline (Day 0) in the quality of life as measured at the End of Treatment |
| Secondary | Shortness of breath measured by San Diego Dyspnea Score | 1 year | Change from Baseline (Day 0) in the quality of life as measured at the End of Treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03231033
GET https://conductscience.org/api/trials/v1/NCT03231033/registered